CARD vs LABD

Key Takeaways

• CARD provides -3x daily inverse exposure to the auto industry via an exchange-traded note (ETN) structure tracking the Prime Auto Industry Index, while LABD delivers -3x daily inverse exposure to the biotechnology sector through a leveraged exchange-traded fund (ETF) tracking the S&P Biotechnology Select Industry Index.
• Both products employ daily-reset leveraged strategies that amplify short-term moves but introduce compounding effects over longer periods, resulting in higher volatility and potential tracking deviation compared to unleveraged benchmarks.
• CARD carries an expense ratio of 0.95% and features a smaller number of constituents (around 24), concentrating risk in the auto sector; LABD has a slightly higher expense ratio of approximately 1.07% and uses derivatives for its biotech exposure.
• Structural differences include CARD’s ETN format (credit risk from issuer) versus LABD’s ETF structure with swap and futures implementation, affecting counterparty and operational considerations.
• These ETFs serve distinct thematic purposes—auto-industry sentiment versus biotech-sector dynamics—making them alternatives for investors seeking inverse leveraged exposure rather than direct competitors.
• Cost efficiency, liquidity profiles, and sector-specific momentum serve as primary differentiators for positioning in inverse strategies during varying market cycles.

Introduction

Investors seeking inverse leveraged exposure often compare products targeting different sectors to align with specific macroeconomic or industry views. CARD and LABD do not compete directly but offer alternative strategies within the broader leveraged and inverse ETF (exchange-traded fund) landscape. CARD focuses on the auto industry, while LABD targets biotechnology, allowing investors to express bearish views on distinct economic drivers such as consumer spending or healthcare innovation. This comparison highlights their structural and exposure differences to support informed allocation decisions.

MAX Auto Industry -3x Inverse Leveraged ETN (CARD) Overview

The MAX Auto Industry -3x Inverse Leveraged ETN (CARD) seeks daily investment results, before fees and expenses, of -300% of the performance of the Prime Auto Industry Index. It is structured as an exchange-traded note (ETN) issued by BMO Financial Group, exposing holders to issuer credit risk in addition to market risk. The product tracks an index with approximately 24 constituents, emphasizing auto manufacturers and related suppliers. Top holdings reflect major auto companies, with sector allocation heavily weighted toward the consumer discretionary and industrials segments of the auto supply chain. CARD maintains an expense ratio of 0.95% and rebalances monthly to maintain its target leverage. Its ETN structure provides direct index exposure without holding underlying securities, distinguishing it from traditional ETFs (exchange-traded funds).

Direxion Daily S&P Biotech Bear 3X Shares (LABD) Overview

The Direxion Daily S&P Biotech Bear 3X Shares (LABD) aims for daily results, before fees and expenses, of -300% of the S&P Biotechnology Select Industry Index. This exchange-traded fund (ETF) uses swaps, futures, and other derivatives to achieve its leveraged inverse objective and resets exposure daily. LABD typically holds a modest number of positions (around 13 in recent filings) while relying on derivatives for the bulk of its exposure. The underlying index covers biotechnology companies classified under the Global Industry Classification Standard (GICS). The ETF carries an expense ratio of 1.07% (net) and maintains high liquidity through active trading. Its structure avoids direct issuer credit risk associated with ETNs but introduces counterparty considerations from derivative counterparties.

Industry and Thematic Backdrop

Both ETFs operate in volatile, innovation-driven sectors sensitive to macroeconomic shifts. The auto industry faces catalysts including electric-vehicle adoption, supply-chain normalization, and interest-rate impacts on consumer financing. Biotechnology remains influenced by regulatory approvals, clinical-trial outcomes, and healthcare spending trends. Capital flows into or out of these areas often reflect broader risk sentiment, with inverse products gaining traction during periods of sector-specific weakness or economic uncertainty. Regulatory developments around emissions standards for autos and drug-pricing policies for biotech represent ongoing structural factors. Investors monitor commodity prices, earnings cycles, and monetary-policy expectations as key drivers affecting relative performance across these themes.

Performance and Positioning Comparison

In recent market cycles, inverse leveraged products like CARD and LABD have exhibited amplified responses to sector rotations and earnings surprises. CARD’s auto-focused exposure tends to react to consumer-demand indicators and manufacturing data, while LABD’s biotech positioning responds more directly to healthcare innovation news and clinical milestones. Over multi-week periods, compounding effects from daily resets can cause both products to diverge from simple multiples of benchmark returns, particularly in trending markets. Relative positioning favors the ETF with stronger sector momentum or lower structural frictions; volatility differences arise from the distinct cyclical sensitivities of autos versus biotech. Liquidity profiles support tactical use, though holding periods beyond a single day require careful monitoring of reset mechanics.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to discover additional opportunities aligned with your investment criteria.

Tickeron AI Verdict

Tickeron’s AI would currently assign a modest probabilistic edge to LABD based on observable factors including its ETF structure, established derivative implementation, and exposure to a sector with distinct volatility characteristics that may align with prevailing momentum signals. Structural strength, cost considerations, and relative diversification within the inverse-leveraged category support this assessment, though outcomes remain subject to evolving sector dynamics and market conditions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations